Skip to main content

Table 1 Initial DMARD regimens

From: Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort

Initial DMARD regimen

Monotherapies (n = 670)

   MTX

43.9%

   SSZ

35.6%

   HCQ

5.4%

   Lef

1.6%

   Others

1.0%

Combination therapies (n = 96)

   MTX + SSZ + HCQ

6.8%

   MTX + SSZ

2.7%

   MTX + HCQ

1.4%

   Others

1.6%

  1. Prevalences of intial DMARD treatments in ERAN participants stratified into monotherapies and combination therapies. MTX methotrexate, SSZ suplphasalazine, HCQ hydroxychloroquine, Lef leflunomide.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us